Search for Spravato reimbursement rates and you will find pages promising to tell you what practices get paid. Be suspicious of all of them, because the manufacturer will not make that claim about its own drug. Janssen’s access and reimbursement guide states plainly that it does not promise or guarantee coverage, levels of reimbursement, payment, or charge.
That is not evasiveness. It is that no such number exists in a form anyone can publish. Your rate is set by your contract with a specific payer, for a specific site of service, in a specific geography, under a specific acquisition model. Change any one of those and the number changes.
So rather than a figure you cannot use, here is what determines your rate, how to find your own, and what the savings program does and does not cover.
The four things that set your number
Your contract. Commercial reimbursement is whatever your negotiated fee schedule says. Two clinics on the same street with the same payer can be paid differently for the same session because they signed different agreements in different years.
How you acquire the drug. Under buy-and-bill you purchase the product, hold the inventory, and bill for both the drug and the administration, typically under the medical benefit, with the claim submitted after the dose. Under a specialty pharmacy arrangement the pharmacy supplies the product patient by patient and bills for it, and you cannot bill for the drug at all. What you can bill for is the observation and monitoring, which is a billable service in its own right, though be aware there is currently no unique designated code describing it. There is also an assignment of benefits route, which lets a practice acquire through a pharmacy when a patient has only a medical benefit.
These are not just administrative preferences. Buy-and-bill puts drug cost on your balance sheet and pays you a margin for carrying it. Specialty pharmacy removes both the cost and the margin. A clinic comparing its Spravato revenue against another clinic’s without knowing which model each runs is comparing nothing.
Site of service. A hospital outpatient department and a physician office are paid on different systems. The same treatment produces a different allowable.
Geography. Medicare payment is adjusted by locality, and commercial contracts follow regional market rates. National averages are the least useful number in the set.
How to find your actual rate
The work is unglamorous and it takes an afternoon.
Start with your own contracts. Pull the fee schedule for each payer and look up the codes you actually bill, which will be the bundled G codes or the unbundled combination depending on your acquisition model. We covered which is which in Spravato CPT codes and billing, including the drug code change that took effect in January.
For Medicare, look up the current allowable for your locality rather than a national figure, and remember that Medicare pays the bundled codes and does not separately pay the drug code.
Then run a benefits verification for each new patient before the first dose rather than after. Confirm whether the plan treats Spravato under the medical or pharmacy benefit, whether prior authorization is required, whether the payer wants a letter of medical necessity, and what the patient’s cost share will be. Janssen’s guidance is that practices should fully review individual payer policies and understand payer-specific requirements, which sounds like boilerplate until the first time a course is half-finished when someone discovers the authorization covered eight sessions.
The withMe savings program, precisely
The SPRAVATO withMe savings program is often described loosely to patients, which causes problems later. The requirements are specific.
| Who qualifies | Age 18 or older, using commercial or private health insurance for their prescribed Spravato, and having an out-of-pocket cost. |
| Who does not | Anyone using a state or federal government-funded healthcare program. Medicare, Medicaid, TRICARE, Department of Defense and Veterans Administration are all excluded. |
| What the patient pays | As little as $10 per treatment for eligible patients. |
| Limits | A maximum program benefit per calendar year, plus quantity limits of three devices per day or 23 devices in a 24-day period, with a separate 24-device allowance in a 24-day period available once per lifetime. |
| Also required | The patient must be enrolled in the SPRAVATO REMS. |
| Income | Patients can participate without sharing income information. |
The government-program exclusion is the one that catches practices out, because it removes a large share of exactly the treatment-resistant population most likely to be referred. A Medicare patient cannot use the copay program, and telling them about it before checking their coverage is a conversation you have to walk back.
Eligibility is checked through the JNJ withMe provider portal, and there is a phone line for confirming which payment route a patient selected.
Denials, and the number worth remembering
Janssen’s access guide repeats a figure from the National Association of Medication Access and Patient Advocacy that 82 percent of medication denials are preventable. That is a trade association’s number about medication denials generally rather than a study about Spravato, so treat it as directional. But the shape of it matches what clinics report: most denials are not clinical disagreements about whether the patient needs treatment. They are administrative.
The recurring causes are worth naming.
A prior authorization obtained for induction that expires partway through maintenance. Documentation that does not evidence the full monitoring period. A code mismatched to the acquisition model. A benefits check done after the first dose rather than before. And treatment started on an assumption about coverage that nobody wrote down.
When a claim is denied and there is an explanation of benefits documenting the reason, an appeal is available, and Janssen publishes a letter of appeal template in its access guide. The template is worth having on file before you need it rather than after.
Common questions
What is the Spravato reimbursement rate?
There is no single national rate to quote. Payment depends on your negotiated contract with each payer, your site of service, your Medicare locality, and whether you buy and bill or receive product from a specialty pharmacy. The manufacturer explicitly declines to guarantee levels of reimbursement. The number you need is in your own fee schedules.
Does Medicare pay for Spravato?
Medicare pays the bundled administration codes rather than paying the drug code separately. The allowable is adjusted by locality, so look up your own rather than a national average. Medicare patients are also excluded from the withMe savings program.
Who is eligible for the SPRAVATO withMe savings program?
Patients aged 18 or over who use commercial or private insurance for their prescribed Spravato, have an out-of-pocket cost, and are enrolled in the REMS. Anyone on a state or federal government-funded program, including Medicare, Medicaid, TRICARE, Department of Defense and Veterans Administration coverage, is excluded.
How much do patients pay with the savings program?
Eligible patients pay as little as $10 per treatment. A maximum program benefit applies per calendar year, along with quantity limits of three devices per day or 23 devices in a 24-day period, plus a separate 24-device allowance in a 24-day period available once per lifetime.
Is buy-and-bill or specialty pharmacy better?
They are different businesses rather than better and worse. Buy-and-bill means you carry drug cost and inventory risk and are paid a margin for it. Specialty pharmacy removes the cost, the risk and the margin, leaving you billing the visit and the monitoring. Which one suits you depends on your cash position, your volume and what your payers will accept.
What should we do before the first dose?
Run a benefits verification, confirm whether prior authorization is required and whether the payer wants a letter of medical necessity, check how many sessions the authorization actually covers, and confirm the patient’s cost share and savings program eligibility. Nearly every preventable denial traces back to one of those five being skipped.
What the rate does not tell you
Clinics tend to treat reimbursement as the number that decides whether a Spravato program works. It is half of one.
The other half is how many of your monitored chair-hours are occupied, and that is set by the REMS rather than by any payer. Two hours of observation per dose, a prescriber on site throughout, twice weekly during induction. We worked through what that does to capacity in Spravato REMS requirements. A well-reimbursed program at half capacity still loses to a modestly reimbursed one that stays full.
We are a marketing agency for mental health clinics, not a billing company or a reimbursement consultancy. Everything above comes from the manufacturer’s published access materials, linked below. Your contracts, your biller and your payers are the authority on your own numbers.
If the gap you are trying to close is empty chairs rather than underpaid claims, that is what we do for Spravato clinics, and the growth audit is free.
Sources
Acquisition models, benefits verification, prior authorization guidance, the denial statistic and the appeal template from Janssen’s SPRAVATO access, coding and reimbursement guide. Savings program eligibility, exclusions, patient cost and quantity limits from the SPRAVATO withMe savings program requirements. Code applicability from Janssen’s coding overview. Last reviewed August 2026.
